(2021) investigated a study involving five patients with relapsed/refractory (R/R) DLBCL, with a median age of 41 years, who had previously undergone CD19/20-CAR-T therapy but experienced disease progression afterward (126). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.